Sign in

    Matthew Taylor • Jefferies

    Matthew Taylor's questions to Medtronic PLC (MDT) leadership

    Matthew Taylor's questions to Medtronic PLC (MDT) leadership • Q4 2025

    Question

    Matthew Taylor requested details on the Diabetes product pipeline, including points of differentiation and upcoming launch timelines.

    Answer

    Executive Que Dallara outlined a robust pipeline, including the U.S. launch of the Simplera Sync CGM in the fall, a recently submitted ACE pump, and a next-generation durable pump (MiniMed Flex) submission planned by year-end. She highlighted differentiation through improved form factors, enhanced algorithms to reduce patient burden, and the value of a single-company ecosystem for customer support.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Medtronic PLC (MDT) leadership • Q4 2025

    Question

    Matthew Taylor requested more information on the Diabetes product pipeline, specifically asking about product differentiation and upcoming timelines.

    Answer

    EVP Que Dallara detailed a robust pipeline, including the U.S. launch of the Simplera Sync sensor in the fall, a pending FDA submission for a pump compatible with an Abbott sensor, and a next-generation durable pump (MiniMed Flex) submission planned by year-end. She highlighted improved form factors, enhanced algorithms, and the customer benefit of a single-company ecosystem.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Globus Medical Inc (GMED) leadership

    Matthew Taylor's questions to Globus Medical Inc (GMED) leadership • Q1 2025

    Question

    Matthew Taylor from Jefferies requested clarification on the top-line guidance, noting that it remained unchanged despite the Nevro deal closing a quarter earlier, which implies a change in underlying assumptions. He also asked for more detail on the cause of the enabling tech deal delays.

    Answer

    COO and CFO Keith Pfeil explained they are being 'conservative on the revenue view' for Nevro to focus on right-sizing the business for profitable growth. CEO Dan Scavilla attributed the enabling tech delays to a longer-than-normal contract redlining process, likely driven by macro challenges at hospitals, rather than any specific customer or deal type.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Establishment Labs Holdings Inc (ESTA) leadership

    Matthew Taylor's questions to Establishment Labs Holdings Inc (ESTA) leadership • Q1 2025

    Question

    Matthew Taylor asked about long-term U.S. market penetration, referencing past commentary on achieving 40-70% share in other markets and questioning where the U.S. might land within that range given its early success. He also asked if guidance assumptions for Mia or Preserve had changed.

    Answer

    CEO Peter Caldini responded that while it is still early in the launch, the company expects to achieve a dominant market share in the United States. He also confirmed that the $8-$10 million revenue guidance for Mia is tracking well and that Preserve's strong early performance was not a significant factor in the initial guidance.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Establishment Labs Holdings Inc (ESTA) leadership • Q4 2024

    Question

    Matthew Taylor asked which incumbent competitor Establishment Labs finds it easier to take market share from in the U.S. He also asked for current thoughts on Mia's potential for market expansion, particularly in Latin America.

    Answer

    CEO Juan Jose Quiros responded that they are taking share from all competitors who value innovation rather than targeting a specific one, and are not competing in the low-price segment. He reaffirmed confidence in Mia's long-term market expansion potential, highlighting the powerful combination of Mia for new patients and Preserve for the core augmentation market.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Establishment Labs Holdings Inc (ESTA) leadership • Q3 2024

    Question

    Matthew Taylor from Jefferies asked for more details on China's performance against 2024 targets, its potential growth contribution in 2025, and the expected impact of the new $50 million strategic financing for the region.

    Answer

    CEO Juan Jose Quiros stated the new financing will advance Motiva's growth and accelerate the regulatory pipeline for Ergonomix2 and Mia in China. Executive Rajbir Denhoy confirmed the company is on track to meet its distributor's $10 million commitment for the year, but noted it was too early to provide specific contribution guidance for 2025.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Lantheus Holdings Inc (LNTH) leadership

    Matthew Taylor's questions to Lantheus Holdings Inc (LNTH) leadership • Q1 2025

    Question

    Matthew Taylor followed up on the 2026 outlook, asking for confirmation of the double-digit growth potential and any additional detail on the magnitude of that growth.

    Answer

    CEO Brian Markison reiterated the company's confidence in achieving double-digit revenue growth in 2026. While he stated it was too early to provide a specific quantum, he listed the key drivers: the potential launches of OCTEVY, PNT2003, and MK-6240, the full-year impact of NEURACEQ, and the continued anchored growth of PYLARIFY and DEFINITY.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Lantheus Holdings Inc (LNTH) leadership • Q4 2024

    Question

    Matthew Taylor asked about the likelihood and timing of CMS moving to an ASP-based reimbursement methodology and how such a change would affect PYLARIFY's growth potential in 2026 or 2027.

    Answer

    CEO Brian Markison characterized a potential move to ASP-based reimbursement as upside to the business. President Paul Blanchfield clarified that the earliest such a change could occur is January 1, 2026, and that the company's current guidance is based on the existing MUC payment policy. He noted that a shift to ASP would further support the payment dynamics for PSMA PET diagnostics.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Lantheus Holdings Inc (LNTH) leadership • Q3 2024

    Question

    Matthew Taylor sought confirmation on the specific unit price for PYLARIFY listed in the CMS final addendum and asked about the company's ability to adjust pricing within its long-term strategic contracts if reimbursement rates improve.

    Answer

    Executive Mark Kinarney stated that the company would not comment on the specifics of its customer partnerships as it is competitive intelligence. President Paul Blanchfield confirmed the reading of the addendum B price but noted CMS reserves the right to make adjustments, while reiterating confidence that PYLARIFY will be paid appropriately in 2025.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Masimo Corp (MASI) leadership

    Matthew Taylor's questions to Masimo Corp (MASI) leadership • Q1 2025

    Question

    Matthew Taylor of Jefferies asked about the potential for further underlying operating margin expansion, the feasibility of mitigating tariff impacts within the current year, and the expected quarterly cadence of the tariff impact.

    Answer

    CFO Micah Young noted that while the business model has high leverage, the company is balancing margin expansion with strategic investments in sales, marketing, and R&D. He explained that significant tariff mitigation is difficult to achieve in 2025 due to timing but actions are being taken to position well for 2026. Young detailed the tariff impact would be $2M in Q2 and step up each quarter, with a more pronounced increase in Q4 at the high end of the guidance range.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Masimo Corp (MASI) leadership • Q3 2024

    Question

    Matthew Taylor questioned the margin progression beyond 2025, asking if the prior cadence of 100 basis points of annual improvement is still a reasonable expectation. He also asked about the future drivers of revenue per driver, specifically the balance between installed base growth and utilization.

    Answer

    CFO Micah Young stated that post-2025, the company expects at least 100 basis points of annual margin improvement, potentially more. Interim CEO Michelle Brennan added that this is balanced with fully resourcing high-growth opportunities. On revenue per driver, Young emphasized that growth will come more from increasing revenue per patient by upselling to premium technologies and monetizing connectivity platforms, rather than just installed base growth. COO Bilal Muhsin confirmed this focus on expanding platform use within the existing base.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Zimmer Biomet Holdings Inc (ZBH) leadership

    Matthew Taylor's questions to Zimmer Biomet Holdings Inc (ZBH) leadership • Q1 2025

    Question

    Matthew Taylor requested a follow-up on tariffs, asking for an estimate of the gross headwind before mitigations and more detail on the primary sources of tariff exposure to better understand potential future changes.

    Answer

    CFO and EVP Suketu Upadhyay clarified that mitigation efforts have centered on optimizing country of origin, transfer pricing, and making strategic sourcing changes. He identified China as the largest area of tariff exposure, both for products shipped into and out of the country. He noted the company took proactive steps, such as building inventory in China ahead of tariffs and evaluating alternative sourcing routes.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Zimmer Biomet Holdings Inc (ZBH) leadership • Q4 2024

    Question

    Matthew Taylor from Jefferies followed up on the Paragon 28 deal, asking about the potential to exceed growth expectations implied by the CVR earnout and the company's capacity for additional M&A.

    Answer

    President and CEO Ivan Tornos confirmed that while the deal model includes appropriate synergies, there is further upside potential from ASC cross-selling, leveraging Paragon's channel for ZBH's trauma products, and international expansion. Regarding future deals, he stated that while the financial "firepower" exists, the immediate priority is to successfully integrate Paragon 28 before considering subsequent acquisitions.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Inmode Ltd (INMD) leadership

    Matthew Taylor's questions to Inmode Ltd (INMD) leadership • Q1 2025

    Question

    Matthew Taylor from Jefferies followed up on the guidance, asking for more specific expectations for Q2 and the phasing for the rest of the year. He also requested details on the source and calculation of the new tariff impact.

    Answer

    CEO Moshe Mizrahy detailed the guidance calculation, which assumes a seasonal pattern with Q2 being stronger ($102M target) and Q3 being slower. He stated if Q2 revenue falls short, around $90-95M, they will lower the full-year guidance. Regarding tariffs, he explained the calculation is based on the transfer price and U.S. business percentage. A 10% tariff translates to a 2-3% impact on gross margin and the bottom line, but he stressed that there is significant confusion and uncertainty around the rules, even among customs authorities and auditors.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Stryker Corp (SYK) leadership

    Matthew Taylor's questions to Stryker Corp (SYK) leadership • Q1 2025

    Question

    Matthew Taylor asked a conceptual question about what would happen if the $200 million tariff impact were to disappear, specifically how much would be reinvested versus flowing to the bottom line.

    Answer

    CFO Preston Wells and CEO Kevin Lobo confirmed that while some of the savings would be reinvested into the business, a removal of tariffs would certainly result in a raise to the bottom-line earnings guidance. Lobo stated unequivocally that earnings would have been raised if not for the tariffs.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Stryker Corp (SYK) leadership • Q3 2024

    Question

    Matthew Taylor asked about the sustainability of positive pricing trends into 2025 and what areas of the business could be a source of upside surprise next year.

    Answer

    CFO Glenn Boehnlein and VP of Finance and IR Jason Beach both deferred providing specific guidance for 2025. They stated that a full outlook on pricing trends and potential areas of growth outperformance would be shared during the January earnings call.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Dexcom Inc (DXCM) leadership

    Matthew Taylor's questions to Dexcom Inc (DXCM) leadership • Q1 2025

    Question

    Matthew Taylor from Jefferies asked for clarification on the U.S. growth improvement, questioning if supply issues impacted revenue and seeking details on the narrowing gap between revenue growth and volume growth.

    Answer

    CFO Jereme Sylvain explained that channel supply levels were normalized by quarter-end, so the reported revenue reflects a true demand pattern. He highlighted a record new patient quarter and suggested volume growth was consistent with the ~25% year-end patient growth rate, confirming the price-to-volume gap is closing as previously guided.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Dexcom Inc (DXCM) leadership • Q4 2024

    Question

    Matthew Taylor inquired about the expected contribution from newly covered non-intensive Type 2 lives in 2025 and the timeline for broader uptake in this population.

    Answer

    CFO Jereme Sylvain confirmed that the new coverage is factored into the 2025 guidance. He stated the immediate work involves educating the market and working with PBMs and CMS to expand access further. He also noted that the ongoing randomized controlled trial (RCT) for this population should have early readouts by the end of the year, which will be used to strengthen the case for broader coverage.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Dexcom Inc (DXCM) leadership • Q3 2024

    Question

    Matthew Taylor asked for a benchmark of Dexcom's progress against its Q2 commentary, specifically regarding new patient start expectations for Q4 and whether the low end of the 2025 long-range plan is still achievable.

    Answer

    CFO Jereme Sylvain confirmed they are on the recovery timeline outlined last quarter, evidenced by record new patients in Q3. He stated that based on current business trends, including DME channel stability and international acceleration, Dexcom is 'on track to hit our $4.6 billion' revenue target and corresponding margins for 2025.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Becton Dickinson and Co (BDX) leadership

    Matthew Taylor's questions to Becton Dickinson and Co (BDX) leadership • Q2 2025

    Question

    Matthew Taylor asked for details on the specific mitigation actions BD is taking to counteract tariff impacts, inquiring about levers like pricing, global footprint adjustments, and changes in sourcing for both the short and long term.

    Answer

    Chairman, CEO and President Thomas Polen outlined a multi-pronged mitigation strategy. Short-term actions include proactively positioning inventory to create a buffer. Longer-term levers involve shifting supply flows, such as sourcing Vacutainers for China from the UK instead of the U.S., and accelerating the ramp-up of its new local Flush facility in China. He also highlighted optimizing raw material sourcing and leveraging the BD Excellence program for margin protection. Polen noted that pricing is a potential third lever if tariffs persist.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Becton Dickinson and Co (BDX) leadership • Q1 2025

    Question

    Matthew Taylor asked for more color on operational performance, specifically the ongoing headwinds from China and research funding that tempered the guidance raise despite a strong quarter and FX impacts.

    Answer

    EVP and CFO Chris DelOrefice emphasized the high quality of Q1 results, with strong margin expansion giving confidence to raise operational EPS guidance despite FX headwinds. Life Sciences President Mike Feld addressed the China situation, noting the impact of a U.S. export ban on the high-end FACSDISCOVER platform, which was unplanned. He added that the company is engaging with policymakers and continues to monitor the cautious research spending environment in the U.S. and China.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Becton Dickinson and Co (BDX) leadership • Q4 2024

    Question

    Matthew Taylor asked for an update on the recently closed Advanced Patient Monitoring (APM) acquisition, inquiring about its long-term growth potential, margin contribution, and integration with BD's broader connected care strategy.

    Answer

    Chairman, CEO, and President Tom Polen stated that the APM integration is going extremely well and that the business is expected to be a durable 6-7% grower. He reiterated the key strategic rationale of combining APM's hemodynamic monitoring with Alaris infusion data to create closed-loop systems that improve patient outcomes, noting that a project to advance this integration is already funded for fiscal 2025.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Tandem Diabetes Care Inc (TNDM) leadership

    Matthew Taylor's questions to Tandem Diabetes Care Inc (TNDM) leadership • Q1 2025

    Question

    Matthew Taylor requested more detail on the early experience with the pharmacy channel and the anticipated timeline for it to become a material part of the business.

    Answer

    CFO Leigh Vosseller highlighted that U.S. lives covered under pharmacy benefits increased from 20% to 30%. She emphasized that this channel significantly lowers patient out-of-pocket costs, addressing a key adoption barrier. While contracts are profitable, she reiterated it will remain a modest contributor in 2025.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Tandem Diabetes Care Inc (TNDM) leadership • Q4 2024

    Question

    An analyst on behalf of Matthew Taylor from Jefferies asked about the progress of the FreeStyle Libre integration and its potential to drive new pump starts.

    Answer

    John Sheridan, President and CEO, clarified that Libre 2 is currently integrated and they are working to bring Libre 3 to market soon for both new and existing users. He highlighted the large market opportunity, noting 300,000-400,000 people with Type 1 diabetes in the U.S. use Libre but not pumps, representing a key growth area for collaboration with Abbott.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Tandem Diabetes Care Inc (TNDM) leadership • Q3 2024

    Question

    Matthew Taylor requested more details on the comment about a "high rate" of conversions from patch pumps.

    Answer

    President and CEO John Sheridan explained that this metric, historically low for years, saw a "meaningful step up" in Q2 which continued into Q3. He attributed this trend to former patch users being attracted to the advanced Control-IQ algorithm in a device that is similarly sized and offers greater wearability.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Edwards Lifesciences Corp (EW) leadership

    Matthew Taylor's questions to Edwards Lifesciences Corp (EW) leadership • Q1 2025

    Question

    Matt Taylor asked if the SAPIEN M3 launch was factored into original guidance and how its launch trajectory might compare to EVOQUE's launch in both Europe and the U.S.

    Answer

    Daveen Chopra, Global Leader of TMTT, confirmed the M3 launch was included in the original guidance. She explained the European launch will be a gradual, controlled rollout focused on training and securing reimbursement. She anticipates the U.S. launch will be slower than EVOQUE's, as M3's indication is for patients unsuitable for TEER or surgery, a more specific population than EVOQUE's broader initial indication.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Edwards Lifesciences Corp (EW) leadership • Q4 2024

    Question

    Matthew Taylor requested a framework for understanding the sources of TMTT growth in 2025, asking for color on the relative contributions from U.S. vs. O.U.S. markets and from mitral vs. tricuspid products, as well as any market share expectations.

    Answer

    CEO Bernard Zovighian emphasized that the company's focus is on creating and defining a new market, not on taking share, pointing to the long-term goal of a $2 billion TMTT business by 2030. Daveen Chopra, Global Leader of TMTT, added that both geographies (U.S. and Europe) and both key products (PASCAL and EVOQUE) are expected to be large, meaningful growth drivers in 2025.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Edwards Lifesciences Corp (EW) leadership • Q3 2024

    Question

    Matthew Taylor asked how quickly a positive sales lift could be expected for TAVR and TMTT if the upcoming EARLY TAVR and tricuspid trial results at TCT are positive.

    Answer

    CEO Bernard Zovighian stated that he could not comment on the potential impact of the blinded, embargoed trial data before its presentation next week, and directed the question to the company's upcoming TCT and investor conference events for a detailed discussion.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Resmed Inc (RMD) leadership

    Matthew Taylor's questions to Resmed Inc (RMD) leadership • Q3 2025

    Question

    Matthew Taylor from Jefferies followed up on the tariff issue, asking about any discussions with the government regarding broader medtech exemptions and the potential for success.

    Answer

    CEO Michael Farrell, speaking as a board member of AdvaMed, stated that while the industry group's goal is a broad exemption for all medtech, he would defer to AdvaMed's CEO on specific negotiations. He stressed that ResMed's own position is secure and the company is prepared to thrive regardless, thanks to its strong balance sheet and operational resilience.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Integra Lifesciences Holdings Corp (IART) leadership

    Matthew Taylor's questions to Integra Lifesciences Holdings Corp (IART) leadership • Q4 2024

    Question

    Matthew Taylor asked about the level of conservatism in the 2025 guidance, specifically concerning potential future ship holds and ongoing Integra Skin supply issues, to understand how de-risked the forecast is.

    Answer

    CFO Lea Knight detailed the guidance structure, which includes provisions for potential new shipping holds ranging from $60 million (high end) to $120 million (low end). CEO Mojdeh Poul added that for Integra Skin, planned maintenance and low safety stock will constrain Q1 supply, with improvement expected as the year progresses.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Integra Lifesciences Holdings Corp (IART) leadership • Q3 2024

    Question

    Matthew Taylor sought clarification on the company's debt covenants, asking for details on how much room they have, and inquired about any potential scenarios that would necessitate a capital raise.

    Answer

    CFO Lea Knight clarified that the current leverage ratio is 4.0x against a covenant threshold of 4.5x, expressing confidence in staying below the limit. She stated that based on the current outlook, which includes potential disruptions, the company does not foresee a need to raise capital.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to LivaNova PLC (LIVN) leadership

    Matthew Taylor's questions to LivaNova PLC (LIVN) leadership • Q4 2024

    Question

    Matthew Taylor of Jefferies inquired about the expected phasing of revenue and EPS throughout 2025, asking if any volatility or special factors should be considered. He also asked for a timeline on when the company would provide more specific details on its plans for the sleep apnea (OSA) asset, including development, potential partnerships, or monetization.

    Answer

    CFO Alex Shvartsburg responded that there is nothing unusual about the 2025 phasing, expecting a typical pattern with Q1 as the lowest revenue quarter and a ramp-up to the highest in Q4. CEO Vladimir Makatsaria outlined the key upcoming milestones for OSA, stating that the 12-month OSPREY study results will be announced in Q2, the FDA submission will occur before the end of Q2, and a full commercialization plan and long-term financial outlook will be presented at an Investor Day in Q4.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Insulet Corp (PODD) leadership

    Matthew Taylor's questions to Insulet Corp (PODD) leadership • Q4 2024

    Question

    Matthew Taylor of Jefferies asked for an update on potential competition and pricing pressure within the pharmacy channel and for management to elaborate on Insulet's defensive moats against these risks.

    Answer

    President and CEO Jim Hollingshead detailed Insulet's significant advantages in the pharmacy channel. He cited years of experience, established PBM relationships, 95% covered lives, and unique Medicare Part D reimbursement. He argued that Insulet's patch pump form factor and pay-as-you-go model are inherently suited to the pharmacy channel, unlike durable pumps, creating a distinct and difficult-to-replicate moat that protects their position.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Insulet Corp (PODD) leadership • Q3 2024

    Question

    Matthew Taylor asked for Insulet's perspective on a competitor's market research suggesting that the intensive Type 2 market could achieve 25% penetration within 3 to 5 years.

    Answer

    President and CEO Jim Hollingshead expressed strong bullishness on the Type 2 market, stating Insulet has a 'clear right to win' due to Omnipod 5's simplicity and pharmacy access. While not directly endorsing the 25% figure, he reiterated his belief that penetration could 'double or triple' in the next few years, with Insulet leading that market development.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to GE Healthcare Technologies Inc (GEHC) leadership

    Matthew Taylor's questions to GE Healthcare Technologies Inc (GEHC) leadership • Q4 2024

    Question

    Matthew Taylor asked for color on segment growth expectations for 2025, with a particular focus on the Pharmaceutical Diagnostics (PDx) segment and the Flyrcado launch. He also requested details on the gating factors for Flyrcado's rollout and reimbursement.

    Answer

    CFO Jay Saccaro stated that PDx growth in 2025 is expected to be broadly in line with 2024, while other segments are anticipated to grow near the corporate average. CEO Peter Arduini elaborated on the Flyrcado launch, confirming the $30 million revenue assumption for 2025 and a methodical rollout through regional contract manufacturing organizations. He noted that reimbursement coding is on track for April and the company is initially targeting centers with existing cardiovascular PET capabilities.

    Ask Fintool Equity Research AI

    Matthew Taylor's questions to Teleflex Inc (TFX) leadership

    Matthew Taylor's questions to Teleflex Inc (TFX) leadership • Q3 2024

    Question

    Matthew Taylor asked for more color on the balloon pump forecast, specifically regarding the visibility from order flow. He also inquired about the magnitude and expected duration of the impact from recent hurricanes and IV saline shortages.

    Answer

    Liam Kelly, Chairman, President and CEO, confirmed that Q4 orders for balloon pumps are in excess of $10 million and that quotation rates have remained strong. Regarding the headwinds, he explained that the hurricane impact was localized to the Southeast, while the saline shortage is viewed as a temporary issue that is already beginning to normalize as suppliers increase imports. The shortage particularly affects urology procedures like UroLift.

    Ask Fintool Equity Research AI